Home » Antibacterial Drug Resistance Market
Antibacterial Drug Resistance Market
Published date: Dec 2021 •Formats:
Request Sample Schedule a Call

Global Antibacterial Drug Resistance Market By Type (Telavancin (Vibativ) , Ceftaroline Fosamil (Teflaro/ Zinforo) , Fidaxomicin (Dificid / Dificlir) , Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio) , Dalbavancin (Dalvance/ Xydalba) , Tedizolid Phosphate (Sivextro) , Oritavancin (Orbactiv/ Nuvocid) , Ceftolozane-Tazobactam (Zerbaxa) , Ceftazidime-Avibactam (Avycaz/ Zavicefta) , and PHASE III DRUGS), By Application (Gram-Positive , and Gram-Negative), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2020-2029

  • Published date: Dec 2021
  • Report ID: 67625
  • Number of Pages: 357
  • Format:
  • keyboard_arrow_up
    • 1. Antibacterial Drug Resistance Market Introduction
      • 1.1. Definition
      • 1.2. Taxonomy
      • 1.3. Research Scope
    • 2. Executive Summary
      • 2.1. Key Findings by Major Segments
      • 2.2. Top strategies by Major Players
    • 3. Global Antibacterial Drug Resistance Market Overview
      • 3.1. Antibacterial Drug Resistance Market Dynamics
        • 3.1.1. Drivers
        • 3.1.2. Opportunities
        • 3.1.3. Restraints
        • 3.1.4. Challenges
      • 3.2. PESTLE Analysis
      • 3.3. Opportunity Map Analysis
      • 3.4. PORTER'S Five Forces Analysis
      • 3.5. Market Competition Scenario Analysis
      • 3.6. Product Life Cycle Analysis
      • 3.7. Opportunity Orbits
      • 3.8. Production Analysis by Region/Company
      • 3.9. Industry chain Analysis
      • 3.10. Marketing Strategy
    • 4. Global Antibacterial Drug Resistance Market Value & Volume ((US$ Mn & '000 Units)), Share (%), and Growth Rate (%) Comparison by Type, 2012-2028
      • 4.1. Global Antibacterial Drug Resistance Market Analysis by Type: Introduction
      • 4.2. Market Size and Forecast by Region
      • 4.3. Telavancin (Vibativ)
      • 4.4. Ceftaroline Fosamil (Teflaro/ Zinforo)
      • 4.5. Fidaxomicin (Dificid / Dificlir)
      • 4.6. Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
      • 4.7. Dalbavancin (Dalvance/ Xydalba)
      • 4.8. Tedizolid Phosphate (Sivextro)
      • 4.9. Oritavancin (Orbactiv/ Nuvocid)
      • 4.10. Ceftolozane-Tazobactam (Zerbaxa)
      • 4.11. Ceftazidime-Avibactam (Avycaz/ Zavicefta)
      • 4.12. PHASE III DRUGS
    • 5. Global Antibacterial Drug Resistance Market Value & Volume ((US$ Mn & '000 Units)), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
      • 5.1. Global Antibacterial Drug Resistance Market Analysis by Application: Introduction
      • 5.2. Market Size and Forecast by Region
      • 5.3. Gram-Positive
      • 5.4. Gram-Negative
    • 6. Global Antibacterial Drug Resistance Market Value & Volume ((US$ Mn & '000 Units)), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
      • 6.1. North America
        • 6.1.1. North America Antibacterial Drug Resistance Market: Regional Trend Analysis
          • 6.1.1.1. US
          • 6.1.1.2. Canada
          • 6.1.1.3. Mexico
      • 6.2.1. Europe
        • 6.2.1. Europe Antibacterial Drug Resistance Market: Regional Trend Analysis
          • 6.2.1.1. Germany
          • 6.2.1.2. France
          • 6.2.1.3. UK
          • 6.2.1.4. Russia
          • 6.2.1.5. Italy
          • 6.2.1.6. Spain
          • 6.2.1.7. Rest of Europe
      • 6.3. Asia-Pacific
        • 6.3.1. Asia-Pacific Antibacterial Drug Resistance Market: Regional Trend Analysis
          • 6.3.1.1. China
          • 6.3.1.2. Japan
          • 6.3.1.3. Korea
          • 6.3.1.4. India
          • 6.3.1.5. Rest of Asia-Pacific
      • 6.4. Latin America
        • 6.4.1. Latin America Antibacterial Drug Resistance Market: Regional Trend Analysis
          • 6.4.1.1. Brazil
          • 6.4.1.2. Argentina
          • 6.4.1.3. Rest of Latin America
      • 6.5. Middle East and Africa
        • 6.5.1. Middle East and Africa Antibacterial Drug Resistance Market: Regional Trend Analysis
          • 6.5.1.1. GCC
          • 6.5.1.2. South Africa
          • 6.5.1.3. Israel
          • 6.5.1.4. Rest of MEA
    • 7. Global Antibacterial Drug Resistance Market Competitive Landscape, Market Share Analysis, and Company Profiles
      • 7.1. Market Share Analysis
      • 7.2. Company Profiles
      • 7.3. AAIPharma Services
        • 7.3.1. Company Overview
        • 7.3.2. Financial Highlights
        • 7.3.3. Product Portfolio
        • 7.3.4. SWOT Analysis
        • 7.3.5. Key Strategies and Developments
      • 7.4. ANTABIO
        • 7.4.1. Company Overview
        • 7.4.2. Financial Highlights
        • 7.4.3. Product Portfolio
        • 7.4.4. SWOT Analysis
        • 7.4.5. Key Strategies and Developments
      • 7.5. Abgentis
        • 7.5.1. Company Overview
        • 7.5.2. Financial Highlights
        • 7.5.3. Product Portfolio
        • 7.5.4. SWOT Analysis
        • 7.5.5. Key Strategies and Developments
      • 7.6. Abbott Laboratories
        • 7.6.1. Company Overview
        • 7.6.2. Financial Highlights
        • 7.6.3. Product Portfolio
        • 7.6.4. SWOT Analysis
        • 7.6.5. Key Strategies and Developments
      • 7.7. Absynth Biologics
        • 7.7.1. Company Overview
        • 7.7.2. Financial Highlights
        • 7.7.3. Product Portfolio
        • 7.7.4. SWOT Analysis
        • 7.7.5. Key Strategies and Developments
      • 7.8. Achaogen
        • 7.8.1. Company Overview
        • 7.8.2. Financial Highlights
        • 7.8.3. Product Portfolio
        • 7.8.4. SWOT Analysis
        • 7.8.5. Key Strategies and Developments
      • 7.9. Acino Holdings
        • 7.9.1. Company Overview
        • 7.9.2. Financial Highlights
        • 7.9.3. Product Portfolio
        • 7.9.4. SWOT Analysis
        • 7.9.5. Key Strategies and Developments
      • 7.10. Aventis Pharma
        • 7.10.1. Company Overview
        • 7.10.2. Financial Highlights
        • 7.10.3. Product Portfolio
        • 7.10.4. SWOT Analysis
        • 7.10.5. Key Strategies and Developments
      • 7.11. Austell Laboratories
        • 7.11.1. Company Overview
        • 7.11.2. Financial Highlights
        • 7.11.3. Product Portfolio
        • 7.11.4. SWOT Analysis
        • 7.11.5. Key Strategies and Developments
      • 7.12. Assembly Biosciences
        • 7.12.1. Company Overview
        • 7.12.2. Financial Highlights
        • 7.12.3. Product Portfolio
        • 7.12.4. SWOT Analysis
        • 7.12.5. Key Strategies and Developments
      • 7.13. Arpida
        • 7.13.1. Company Overview
        • 7.13.2. Financial Highlights
        • 7.13.3. Product Portfolio
        • 7.13.4. SWOT Analysis
        • 7.13.5. Key Strategies and Developments
      • 7.14. Demuris
        • 7.14.1. Company Overview
        • 7.14.2. Financial Highlights
        • 7.14.3. Product Portfolio
        • 7.14.4. SWOT Analysis
        • 7.14.5. Key Strategies and Developments
      • 7.15. Evolva Holding
        • 7.15.1. Company Overview
        • 7.15.2. Financial Highlights
        • 7.15.3. Product Portfolio
        • 7.15.4. SWOT Analysis
        • 7.15.5. Key Strategies and Developments
      • 7.16. ContraFect
        • 7.16.1. Company Overview
        • 7.16.2. Financial Highlights
        • 7.16.3. Product Portfolio
        • 7.16.4. SWOT Analysis
        • 7.16.5. Key Strategies and Developments
      • 7.17. Cerexa
        • 7.17.1. Company Overview
        • 7.17.2. Financial Highlights
        • 7.17.3. Product Portfolio
        • 7.17.4. SWOT Analysis
        • 7.17.5. Key Strategies and Developments
      • 7.18. GSK
        • 7.18.1. Company Overview
        • 7.18.2. Financial Highlights
        • 7.18.3. Product Portfolio
        • 7.18.4. SWOT Analysis
        • 7.18.5. Key Strategies and Developments
      • 7.19. InterMune
        • 7.19.1. Company Overview
        • 7.19.2. Financial Highlights
        • 7.19.3. Product Portfolio
        • 7.19.4. SWOT Analysis
        • 7.19.5. Key Strategies and Developments
      • 7.20. Isis Pharmaceuticals
        • 7.20.1. Company Overview
        • 7.20.2. Financial Highlights
        • 7.20.3. Product Portfolio
        • 7.20.4. SWOT Analysis
        • 7.20.5. Key Strategies and Developments
      • 7.21. Lyndra
        • 7.21.1. Company Overview
        • 7.21.2. Financial Highlights
        • 7.21.3. Product Portfolio
        • 7.21.4. SWOT Analysis
        • 7.21.5. Key Strategies and Developments
      • 7.22. Microbecide
        • 7.22.1. Company Overview
        • 7.22.2. Financial Highlights
        • 7.22.3. Product Portfolio
        • 7.22.4. SWOT Analysis
        • 7.22.5. Key Strategies and Developments
    • 8. Assumptions and Acronyms
    • 9. Research Methodology
    • 10. Contact
    • AAIPharma Services
    • ANTABIO
    • Abgentis
    • Abbott Laboratories
    • Absynth Biologics
    • Achaogen
    • Acino Holdings
    • Aventis Pharma
    • Austell Laboratories
    • Assembly Biosciences
    • Arpida
    • Demuris
    • Evolva Holding
    • ContraFect
    • Cerexa
    • GSK
    • InterMune
    • Isis Pharmaceuticals
    • Lyndra
    • Microbecide
  • settingsSettings

Related Reports

Our Clients

  • Our Clients
Inquiry Before Buying

Antibacterial Drug Resistance Market
  • 67625
  • Dec 2021
    • ★★★★★
      ★★★★★
    • (25)
  • US $5,999
    US $2,999
  • US $7,999
    US $3,499
  • US $12,999
    US $4,499
Buy Now
✖
Request a Sample Report
We'll get back to you as quickly as possible

Single User
$5,999
$2,999
USD / per unit
save 50%
 Multi User
$7,999
$3,499
USD / per unit
save 55%
 Corporate User
$12,999
$4,499
USD / per unit
save 65%
e-Access
Data Set (Excel)
Print
Company Profile Library Access
Interactive Dashboard
Free Custumization No up to 10 hrs work up to 30 hrs work
Accessibility 1 User 2-5 User Unlimited
Analyst Support up to 20 hrs up to 40 hrs up to 50 hrs
Benefit Up to 20% off on next purchase Up to 25% off on next purchase Up to 30% off on next purchase
Buy Now ($ 2,999)Buy Now ($ 3,499)Buy Now ($ 4,499)
Find Help
Legal
Explore